BridgeBio Pharma, Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Feb 25, 2022 and accepted by EDGAR at Feb 25, 2022, 06:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $69.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $451.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2021-01-01 to 2021-12-31 | $192.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$576.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $46.8m | us-gaap:InterestExpense |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$586.5m | us-gaap:ProfitLoss |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$497.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $13.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $200.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $393.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $888.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $1.01bn | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $135.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $1.88bn | us-gaap:Liabilities |
| Long-term debt | At period end2021-12-31 | $430.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2021-12-31 | −$870.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-002030. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.